Germany's New Pharmaceutical Stockpiling Requirement: A Game Changer for Drug Availability
A recent legislative change in Germany has led to the implementation of a six-month pharmaceutical stockpiling requirement to combat drug shortages. This policy aims to reduce supply chain disruptions by ensuring consistent availability of medications. An analysis conducted under the perspective of German social health insurance (SHI) assesses the impact and cost-effectiveness of this regulation. Using data on past drug shortages in Germany from 2012 to 2023, the analysis simulated the prevention of drug shortages under extended inventory conditions.
The findings reveal that maintaining a six-month inventory could potentially prevent about 70% of drug shortages. Incremental benefits of longer inventory periods diminish due to increasing cost-per-quality-adjusted life year (QALY) ratios. The six-month stockpiling requirement shows promise in reducing supply bottlenecks effectively and economically, with maximum cost-effectiveness projected at 922 days under current cost assumptions.
Additional factors influencing the analysis include the First In, First Out (FIFO) compliance in inventory turnover, the number of drug shortages, and the valuation of health gains. An enhanced strategic inventory management approach could significantly strengthen supply chains, ensuring medication availability and improving patient outcomes.
The policy also highlights the potential role of strategic inventory management to enhance the reliability of pharmaceutical supply chains, as studies emphasize its importance in healthcare. Various models suggest optimizing inventory management can manage costs effectively while maintaining patient service levels.
In 2023, drug shortages persisted across Europe, with 65% of countries witnessing unchanged or exacerbated supply issues. Although causes vary due to healthcare systems and market conditions, common challenges include manufacturing issues, regulatory pressures, and supply chain disruptions.
To mitigate such shortages, Germany's Federal Cabinet introduced several regulatory amendments on April 5, 2023, including adjustments to price rules and rebate contracts. However, a proposed three-month stockpiling requirement for off-patent drugs was omitted from the final law passed on June 23, 2023, which mandated a six-month stockpile for rebated drugs.
Crucially, the stockpiling provision is aimed at shortages classified as "clinically relevant" by the Federal Institute for Drugs and Medical Devices (BfArM). Employing a health opportunity cost-based threshold, the financial implications of the policy were examined, ensuring the avoidance of clinically relevant shortages provides cost-effective health benefits.
The analysis underscores the necessity of ongoing monitoring and reassessment as new evidence emerges, especially concerning compliance with FIFO procedures and the financial implication of public spending on health. The study supports the increased stability and efficiency of Germany's drug supply chain facilitated by the stockpiling mandate.